Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Better Delineation of YY1 Related Phenotype and Epigenetic Signatures.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04381715
Recruitment Status : Unknown
Verified May 2020 by University Hospital, Montpellier.
Recruitment status was:  Recruiting
First Posted : May 11, 2020
Last Update Posted : May 14, 2020
Information provided by (Responsible Party):
University Hospital, Montpellier

Brief Summary:

YY1 related disorder, also known as Gabriele-de-Vries syndrome, is mainly characterised by developmental delay (DD) and intellectual disability (ID), ranging from mild to severe, and neuroimaging abnormalities.

The aims of this study are first to better delineate the clinical phenotype, as well as the neuropsychological profile, and the brain MRI characteristics; and, second, to study the epigenetic signatures in a cohort of individuals with YY1 intragenic pathogenic variants. This work will conduct to a MD thesis of a clinical resident geneticist in France.

Physician that will participate will fill an Excel sheet regarding the clinical and neuropsychological assessment. The investigators will be also happy to have either CD-ROM or a link to have access to the brain MRI data as well as a DNA sample with a minimum 0.5ug of peripheral blood genomic DNA. The investigators will gather the DNA in Montpellier genetic lab (Dr Mouna BARAT) and send the batch to the Dr Sadikovic' lab.

Between 2019 and 2020, the investigators have already recruited data from individuals with YY1 pathogenic variants from several European and American genetic centres.

Condition or disease Intervention/treatment
YY1 Related Disorder Genetic: Epigenetic signatures

Detailed Description:

The investigators aim to better understand and delineate the genetic syndrome YY1 (a.k.a. Gabriele-de-Vries syndrome).

This genetic disorder was described in June 2017 in the American Journal of Human Genetics (PMID 28575647).

Since this first publication of 23 individuals carrying the pathogenic mutation YY1, another individual has been reported in the literature (PMID 30549423).

In addition, the first paper focused on the clinical description as well as the effect of pathogenic YY1 variations in chromatin regulation.

The investigators are seeking to better define the phenotype of individuals with pathogenic variants of YY1, to better understand intellectual functioning as well as the strengths and weaknesses of intellectual functioning by collecting standardized neuropsychological assessments already performed such as WPPSI/WISC and WAIS. For this purpose, the investigators will gather clinical and neuropsychological data already carried out in the context of care.

The investigators also aim to gather the cerebral MRI scans already performed in order to better delimit the cerebral anomalies observed in individuals and if the sequence is adapted, the investigators will perform VBM studies.

Finally, the investigators will attempt to identify an epigenetic signature in this genetic disease. To this end, the investigators will collect genomic DNA from peripheral blood already collected for genetic analysis and send an anonymized batch of samples to our collaborator, Dr. Bekim Sadicovik. Dr. Bekim Sadicovik and his team will compare the epigenetic DNA methylation-type markers with the corresponding sex and age controls. If specific probes are abnormally methylated in YY1 individuals, this will determine a disease-specific epigenetic signature. The investigators will then be able to propose an epigenetic signature for individuals with uncharacterized YY1 variations (class 3, VUS). This method will make it possible to define whether the variation is responsible for the disease or not without going through functional analysis steps that are difficult to implement routinely.

The expected benefits are a better understanding of YY1 disease, keys to neuropsychological rehabilitation, a better understanding of human brain functions, the possibility of proposing an epigenetic signature for people in whom it is not possible to decide whether a variation in the YY1 gene is pathological or not

Layout table for study information
Study Type : Observational
Estimated Enrollment : 10 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: YY1 Related Disorder : Clinical Phenotype, Neuropsychological Profile, Brain MRI Characteristics and Epigenetic Signatures.
Actual Study Start Date : May 1, 2020
Estimated Primary Completion Date : December 1, 2020
Estimated Study Completion Date : December 1, 2020

Group/Cohort Intervention/treatment
YY1 intragenic pathogenic variant
Genetic: Epigenetic signatures
Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)

Primary Outcome Measures :
  1. YY1 related clinical and neuropsychological phenotype phenotype and brain MRI description [ Time Frame: 1 day ]
    YY1 related clinical and neuropsychological phenotype phenotype and brain MRI description

  2. Evolution of genetic data [ Time Frame: 1 day ]
    Evolution of genetic data

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Individuals with YY1 intragenic pathogenic SNV (Single Nucleotide Variant)

Inclusion criteria:

- YY1 intragenic pathogenic SNV (Single Nucleotide Variant)

Exclusion criteria:

  • no pathogenic SNV in YY1
  • no consent for the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04381715

Layout table for location contacts
Contact: David GENEVIEVE, MH PD 04 67 33 61 04 ext 33
Contact: Pauline MONIN, Resident

Layout table for location information
UH Montpellier Recruiting
Montpellier, France, 34295
Contact: David GENEVIEVE   
Contact: Pauline MONIN, Resident   
Sub-Investigator: Bekim SADIKOVIC, DR         
Sub-Investigator: Florian CHERIK, DR         
Sponsors and Collaborators
University Hospital, Montpellier
Layout table for investigator information
Principal Investigator: David GENEVIEVE Department of Medical Genetics
Layout table for additonal information
Responsible Party: University Hospital, Montpellier Identifier: NCT04381715    
Other Study ID Numbers: RECHMPL20_0272
First Posted: May 11, 2020    Key Record Dates
Last Update Posted: May 14, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: NC

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Montpellier: